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Should Patient-Rated Performance Status Affect Treatment
Decisions in Advanced Lung Cancer?
Esther Dajczman, RN, MScA,*† Goulnar Kasymjanova, MD, PhD,* Harvey Kreisman, MD,*
Nelda Swinton, PDt,* Carmela Pepe, MD, FRCP(C),*‡ and David Small, MD, FRCP(C)*‡
Introduction: The Eastern Cooperative Oncology Group (ECOG)
score is a well known prognostic factor and almost always used to
determine eligibility for clinical trials. The patient-rated perfor-
mance status score (Pt-PS), section of the patient generated subjec-
tive global assessment scale, has identical criteria to the physician-
rated ECOG scale (MD-PS). We compared the Pt-PS with MD-PS
in patients with advanced non-small cell lung cancer and compared
the effect of each rating on eligibility for a hypothetical clinical trial.
Methods: Consecutive patients with newly diagnosed advanced
non-small cell lung cancer completed a patient generated subjective
global assessment self-rated questionnaire, which was then corre-
lated (kappa statistic) with the ECOG PS recorded at the same time.
Patients were treated with standard chemotherapy. Survival was
determined using Kaplan-Meier statistics.
Results: One hundred nine patients (M:F–54:55) were recruited.
Pt-PS differed from MD-PS in 59 (54%) instances (p  0.0001).
When scores were not congruent, 41/59 (69%) patients evaluated
themselves as having a worse PS than the physician’s rating. Pt-PS
was 0 to 1 in 60 (55%) patients whereas MD-PS was 0 to 1 in 78
(72%) patients. The functional status irrespective of evaluator was
predictive of survival (p  0.001 for MD-PS and p  0.001 for
Pt-PS). However, the median survival in those with MD-PS 2 was
3.3 (CI; 1.7–4.9) months whereas individuals with Pt-PS 2 had a
median survival of 6.2 (CI; 5.4–6.9) months.
Conclusions: Pt-PS and MD-PS were not congruent in over half of
the cases, with Pt-PS scores usually poorer. Almost half the patients
would have excluded themselves from a hypothetical clinical trial
(Pt-PS 2). This requires prospective evaluation.
Key Words: NSCLC, ECOG PS, Patient-rated activity level, Con-
gruency of PS rating, Survival.
(J Thorac Oncol. 2008;3: 1133–1136)
Use of a simple scoring system such as the EasternCooperative Oncology Group (ECOG) or Karnofsky
Performance status score for estimating a patient’s ability to
perform daily activities is used throughout oncology prac-
tice.1 This simple numerical guide to evaluate patients’ gen-
eral well being is used to predict not only just survival, but
also the probability of response, treatment toxicity, and qual-
ity of life.2 These scales are, therefore, used to determine
suitability for treatment, and are often used as entry criteria or
eligibility requirements for clinical trials.3–6
The assessment of patient-rated performance status
(Pt-PS) has been done in a number of different cancer
populations, and a lack of congruency between health care
professional and patient estimates has been documented. In
patients with lung cancer, Blagden et al. reported 50% con-
gruency between patient and physician estimates of perfor-
mance status in a mixed population.1 Similarly, Ando et al.
found 53% congruency in a sample of advanced non-small
cell lung cancer (NSCLC) patients who rated themselves
using the ECOG PS questionnaire.1 These trials both showed
similar rates of agreement; however, neither study used
questionnaires designed specifically for patient use. The pa-
tient generated subjective global assessment (PG-SGA) scale
is a validated self administered scale that is used to assess
nutritional and functional status.7–9 Box 4 of the tool is used
for patient-rated activity and function and is very similar to
the ECOG scale used by health care personnel to evaluate
patients (Table 1).
We sought to determine the congruency between phy-
sician-rated performance status (MD-PS) and Pt-PS scores
evaluated shortly after diagnosis of advanced NSCLC and
before any cancer treatment. We explored the level of con-
gruency between scores and applied these to the entry criteria
of a hypothetical clinical trial. We also evaluated survival
with respect to the two performance status ratings.
PATIENTS AND METHODS
One hundred nine patients with newly diagnosed ad-
vanced NSCLC, seen prospectively in the Pulmonary Oncol-
ogy Clinic of the Sir Mortimer B. Davis Jewish General
Hospital were recruited from April 2005 to May 2007.
Assessment of performance status was accomplished
through utilization of the ECOG performance status scale
rated by physicians and the PG-SGA questionnaire completed
by patients. The assessments were done at baseline before
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any treatment. The physician was blinded to the patient’s
PG-SGA score; nor did the patient have access to the physi-
cian rating. Patients were already aware of the diagnosis, but
the PG-SGA was administered before disclosure of any new
medical test results to be given on that day.
The ECOG (MD-PS) performance status is a 6 point
validated functional activity scale, which is widely and rou-
tinely used to evaluate the patient’s condition. It has the
advantage of being easy to use in the clinical setting, and is
known to be well correlated with survival.2 The Activities
and Function subscale (Box 4), (Pt-PS) is scored from 0
(normal with no limitations) to 4 (pretty much bedridden,
rarely out of bed) (Table 1).
Ratings were categorized as1 and2 for purposes of
comparison, and thus similar to that used for eligibility in
most clinical trials. Physician and patient ratings of perfor-
mance status were then correlated using a kappa statistic.
Patients were treated with standard chemotherapy, and sur-
vival analysis was performed using a Kaplan-Meier analysis.
The study was approved by the hospital research and ethics
committee.
RESULTS
One hundred nine consecutive patients, 54 males and
55 females, with a diagnosis of Stage III or IV NSCLC and
able to complete the PG-SGA self rated questionnaire (avail-
able in both French and English), completed the study. The
majority of patients (83%) presented with more advanced
disease (3b pleural effusion/4), and almost half the group
(48%) was comprised of older patients (65 years). Initial
treatment was consisted of chemotherapy in 88 (81%) pa-
tients of whom 65 (74%) received platinum-based doublet
therapy. The remaining 21 patients received best supportive
care with palliative radiotherapy as their initial treatment.
Seventy-eight (72%) patients had an MD-PS of 1,
whereas only 60 (55%) had a Pt-PS of 1. MD-PS rating of
2 was seen in 31 (28%) patients, compared with 49 (45%)
by Pt-PS. Pt-PS was not congruent with MD-PS in 59 (54%)
cases (p  0.0001), and when scores were not congruent,
41/59 (69%) patients evaluated themselves more pessimisti-
cally than the physician (Table 2). Performance status was
associated with survival irrespective of whether MD-PS or
Pt-PS was used (p  0.001 for MD-PS and p  0.001 for
Pt-PS) (Table 3). The survival of patients with PS 0 to 1 was
the same irrespective of rater (Figure 1). However, the me-
dian survival in 31 patients with MD-PS 2 was 3.3 (CI;
1.7–4.9) months, whereas 49 patients with Pt-PS 2 had a
median survival of 6.2 (CI; 5.4–6.9) months (Figure 1).
The level of agreement between MD-PS and Pt-PS with
respect to entry into a hypothetical clinical trial where eligi-
bility required a performance status of 1, was only moder-
ate (kappa coefficient  0.42). In 79 (72%) cases, MD-PS
and Pt-PS were congruent both rating PS as 0 to 1, however,
in 30 (28%) cases there was a lack of agreement on eligibility
for the trial. Of those 30 cases where there was disagreement,
24 (80%) patients would have excluded themselves from the
hypothetical trial whereas their physicians would have in-
cluded them (Table 4). The median survival of those 24
patients was 8.7 (CI; 5.2–12.2) months. The remaining 6
patients who would have been excluded by physicians had a
survival of 2.8 (CI; 1.1–4.5) months (p  0.01).
DISCUSSION
We found only moderate correlation between physician
and patient ratings of performance status. In 54% of cases
TABLE 2. Patients’ and Physicians’ Agreement in Rating of PS
MD-PS
Score 0 1 2 3 4 Total
Pt-PS
0 7 12 19
1 5 30 5 1 41
2 3 6 6 15
3 3 11 11 7 32
4 1 1 2
Total 18 60 22 9 109
PS, performance status; MD, physician rated; Pt-PS, patient rated performance
status.
TABLE 1. Performance Status as Rated by ECOG and Self-Rated (PG-SGA) Scales
ECOG/WHO Score (MD-PS) PG-SGA: Activities and Function (Pt-PS)
0 Fully active, able to carry on all predisease performance without
restriction
Normal with no limitations
1 Restricted in physically strenuous activity, but ambulatory and able
to carry out work of a light and sedentary nature (i.e., light
housework, office work)
Not my normal self, but able to be up and about with fairly
normal activities
2 Ambulatory and capable of all self-care unable to carry out any
work activities. Up and about more than 50% of waking hours
Not feeling up to most things, but in bed or chair less than half
the day
3 Capable of only limited self-care, confined to bed or chair more than
50% of waking hours
Able to do little activity and spend most of the day in bed or
chair
4 Completely disabled. Cannot carry on any self-care. Totally confined
to bed or chair.
Pretty much bedridden, rarely out of bed
5 Dead
ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization; PG-SGA, patient generated subjective global assessment; MD-PS, physician rated performance
status; Pt-PS, patient rated performance status.
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Pt-PS and MD-PS were not congruent, with patients typically
more pessimistic (69%) about their functional status than are
their physicians. The discordance would have affected eligi-
bility into a hypothetical clinical trial where eligible patients
would have a performance status score of 0 to 1. Most of the
patients (24/30) who rated their performance status differ-
ently from physicians, would have excluded themselves from
entry. Median survival in Pt-Ps 1 and 2 was similar; however,
survival was different in MD-PS 1 and 2, indicating that
physicians’ ability to discriminate between patient groups
was possibly superior.
The lack of congruency was previously reported in
the literature in a variety of cancer population samples,
some of which included early stage non-small lung cancer
as well as patients with small cell lung cancer.5,10 –12
However, the reasons for this have not been thoroughly
investigated or well understood although various authors
have alluded to a number of possible explanations. Our
findings agree with Blagden et al.,5 who also described
patient pessimism when reporting the incongruency be-
tween physician and patient performance status scores.
The authors speculated that perhaps this finding could be
attributed to physical or psychologic comorbidity that may
have been overlooked by oncologists. Newell et al.13
reported that medical oncologist’s perceptions may not
accurately reflect their patients’ physical and psychosocial
experiences. These factors may, therefore, confound the
process of choosing treatments, especially those that in-
volve clinical trials.
FIGURE 1. Kaplan-Meier survival curves of performance status rated by patients (Pt-PS) and physicians (MD-PS) i.e. Kaplan-
Meier survival curve of performance status rated by patients (Pt-PS) and physicians (MD-PS). . . . . . PS 0 to 1. — PS 2.
TABLE 3. Survival According to PS Rated by Patients (Pt-PS) and Physicians (MD-PS)
Pt-PS n Survival (mo) Median (CI) MD-PS n Survival (mo) Median (CI)
0 19 14.4 (12.016.8) 0 18 10.7 (8.112.3)
1 41 8.3 (6.310.3) 1 60 9.9 (8.411.5)
2 15 8.2 (3.511.1) 2 22 4.6 (2.65.6)
3 32 5.0 (0.57.1) 3 9 2.8 (2.72.8)
4 2 1.7 4 0 0
Total 109 Total 109
p  0.001 p  0.001
PS, performance status; Pt, patient rated; MD, physician rated.
TABLE 4. Agreement on Eligibility for Hypothetical Trial
(PS  0–1) Based on Rating
MD-PS
Eligible
Not
Eligible Total
Pt-PS
Eligible 54 6 60
Not eligible 24 25 49
Total 78 31 109
Level of agreement (Kappa coefficient)  0.42 (moderate agreement).
PS, performance status; MD, physician rated; Pt, patient rated.
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To date Pt-Ps has not been used to influence decision
making with respect to treatment options despite a docu-
mented lack of congruency between physician and patient
estimates. Although specific to evaluating activity level as a
measure of functional status, the ECOG scale may actually
function as a surrogate for overall patient distress or wellbe-
ing.14 As designed, it is not a very linear scale, and the
potential for assessor bias may involve the decision to take
other factors into account besides activity level. Consider-
ation of Pt-Ps may thus be very important given patient
pessimism when a lack of congruency exists, and particularly
when determining the aggressivity of treatment and when
entering individuals on clinical trials.15 The possibility of
selection bias is particularly important in view of the rela-
tively small percentage of patients treated on clinical trials,
thus making application of findings from any trial difficult.16
Although both physician and patient performance sta-
tus ratings were predictive of survival in the current study, the
median survival times differed for PS2. However, patients’
evaluation with respect to PS 1 versus 2 did not result in
different survival. It seems that physicians are better able to
separate PS 1 from PS 2, which makes a distinction between
those who are judged as able to benefit from more aggressive
therapy and those who are not. Previous authors have simi-
larly documented a survival difference between raters. Ando
et al. reported that in their study of performance status
assessed by oncologists, nurses, and patients, survival was
well correlated with each group’s assessment.10 Among the
three groups of evaluators the oncologist’s assessment was
best fitted with the observed survival data.
It is very difficult to assess the true accuracy or predic-
tive value of oncologists’ versus patients’ assessments on
survival. The inherent bias related to physician treatment
allocation based on their own overall assessment of clinical
status is like a self fulfilling prophecy and was well discussed
by Blagden et al.5 They point out that survival is impacted
upon by treatment allocation which is ultimately based on the
oncologist’s assessment, not the patient’s. In view of the
minor benefit of treatment in NSCLC, this bias might be
minimized; nevertheless, it is important to be cognizant of its
potential impact on survival.
In conclusion, Pt-PS and MD-PS were not congruent in
over half of patients at diagnosis. When discordant, patients
estimated PS to be poorer than MD estimates. Prospective
secondary analysis using Pt-PS are needed to determine
whether this difference between Pt-PS and MD-PS has an
impact on survival in clinical trials. Furthermore, research
could focus on the underlying causes of this discrepancy,
particularly if depression or distress is the major reason for
the poorer rating, and not the level of activity.
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